Form 4: Adicet Bio SVP & Chief Medical Officer Francesco Galimi Reports Stock Option Grant

Francesco Galimi, SVP & Chief Medical Officer of Adicet Bio, Inc., reports the acquisition of stock options.

Summary

• On June 5, 2024, Francesco Galimi, SVP & Chief Medical Officer of Adicet Bio, Inc., filed a Form 4.
• The filing reports the grant of stock options to purchase 375,077 shares of Adicet Bio's common stock.
• The exercise price of the stock options is $2.53.
• The options vest in 48 equal monthly installments starting January 26, 2024, contingent upon continued service with the company.
• The expiration date for the options is January 25, 2034.
• Following the transaction, Galimi directly owns 375,077 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule incentivizes continued service with the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The size of the grant is likely determined by a number of factors including the executive's role, company performance, and industry benchmarks.
• Comparable companies such as CRISPR Therapeutics, Beam Therapeutics, and Intellia Therapeutics also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates